Arca
Skip to content
Tools
Tools

RNA

Nucleic acid in Homo sapiens that 12 drugs act on.

  • Drugs that act on it: 12
  • Approved: 7
  • In phases 1 to 3: 5
  • Sponsors: 9

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 10
  • Protein or peptide 1
  • Other 1

Approved7

  • Fluorouracil
  • Capecitabine
  • Azacitidine
  • Cytarabine
  • Tegafur
  • Carmustine
  • Hydroxystilbamidine

Phase 32

  • Doxifluridine
  • Elacytarabine

Phase 23

  • RSLV-132
  • Aspacytarabine
  • Bleomycin A6

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 8 of 12 act as: RNA inhibitor; the rest name their own mechanism.
    FluorouracilApprovedSpectrum PharmaceuticalsSmall moleculeInhibitor1,283
    CapecitabineBoxed warningApprovedCheplapharmSmall moleculeInhibitor876
    AzacitidineApprovedBristol-Myers SquibbSmall moleculeInhibitor443
    CytarabineBoxed warningApprovedTeva Pharmaceutical IndustriesSmall moleculeInhibitor419
    TegafurApprovedOno PharmaceuticalSmall moleculeInhibitor72
    CarmustineApprovedAvet LifesciencesSmall moleculeInhibitor32
    HydroxystilbamidineApproved—Small moleculeInhibitor0
    DoxifluridinePhase 3—Small moleculeDisrupting agentRNA disrupting agent0
    ElacytarabinePhase 3Clavis PharmaSmall moleculeInhibitor0
    RSLV-132Phase 2Resolve TherapeuticsOtherHydrolytic enzymeRNA hydrolytic enzyme1
    AspacytarabinePhase 2BioSight Ltd.Small moleculeDisrupting agentRNA disrupting agent0
    Bleomycin A6Phase 2—Protein or peptideDisrupting agentRNA disrupting agent0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 42 in all, from ClinicalTrials.gov.
    Serplulimab Plus Bevacizumab and Chemotherapy for Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer After First-Line Anti-EGFR TherapyCapecitabine, FluorouracilPhase 2Not yet recruitingChina Medical University, ChinaNov 20, 2026
    A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AMLAzacitidine, CytarabinePhase 2Not yet recruitingDana-Farber Cancer InstituteNov 19, 2026
    Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)CytarabinePhase 3Not yet recruitingUniversity Hospital, ToulouseNov 19, 2026
    A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)CytarabinePhase 4Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNov 19, 2026
    HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric CancerCapecitabinePhase 2Not yet recruitingShanghai Zhongshan HospitalNov 17, 2026
    Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5CapecitabinePhase 3Not yet recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNov 17, 2026
    Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal CancerFluorouracilPhase 2Not yet recruitingDamanhour UniversityNov 17, 2026
    RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ AdenocarcinomaCapecitabine, FluorouracilPhase 2 / Phase 3Not yet recruitingRemeGen Co., Ltd.Nov 13, 2026
    Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling.CytarabinePhase 4RecruitingLiverpool John Moores UniversityNov 13, 2026
    Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic SyndromesAzacitidinePhase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo UniversityNov 12, 2026
    SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)Capecitabine, FluorouracilPhase 3Not yet recruitingFudan UniversityNov 12, 2026
    QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma PatientsFluorouracilPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNov 12, 2026
    Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaTegafurPhase 2RecruitingBeijing Tsinghua Chang Gung HospitalNov 12, 2026
    A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsAzacitidinePhase 3RecruitingBeijing InnoCare Pharma Tech Co., Ltd.Nov 9, 2026
    Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast CancerCapecitabine, Fluorouracil—Active, not recruitingPeking Union Medical College HospitalNov 9, 2026
    GK01 Cell Therapy in Gastric Cancer With Peritoneal MetastasisTegafurPhase 1Not yet recruitingRuijin HospitalNov 6, 2026
    Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal CancerCapecitabine, FluorouracilPhase 3Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.Nov 4, 2026
    Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract CancerCapecitabinePhase 3Not yet recruitingZhai WenlongNov 4, 2026
    A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerFluorouracilPhase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 4, 2026
    Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCytarabinePhase 1Not yet recruitingCity of Hope Medical CenterNov 3, 2026
    MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )CytarabineNot applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang UniversityOct 29, 2026
    Sonrotoclax Plus Azacitidine in Patients With MDS-IB2AzacitidinePhase 1 / Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of MedicineOct 21, 2026
    Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort StudyTegafurPhase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOct 14, 2026
    Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLAzacitidinePhase 2Not yet recruitingRutgers, The State University of New JerseyOct 9, 2026
    Low Dose Induction for Pediatric Acute Myeloid Leukemia PatientsCytarabineNot applicableRecruitingAzza Shibl SayedOct 9, 2026
    Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerTegafurPhase 2RecruitingRuijin HospitalOct 9, 2026
    Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung CancerAzacitidinePhase 1 / Phase 2Not yet recruitingNob Hill Therapeutics, Inc.Oct 8, 2026
    Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Azacitidine, CytarabinePhase 2Not yet recruitingNational Cancer Institute (NCI)Oct 7, 2026
    Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AMLAzacitidinePhase 1Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaSep 18, 2026
    A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaTegafurPhase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou UniversitySep 18, 2026
    A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaTegafurPhase 3Not yet recruitingOno Pharmaceutical Co., Ltd.Sep 14, 2026
    A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.TegafurPhase 2RecruitingXijing HospitalAug 26, 2026
    Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCLCarmustinePhase 2Not yet recruitingRuijin HospitalAug 19, 2026
    Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction AdenocarcinomaTegafurPhase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical UniversityAug 19, 2026
    CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.CarmustinePhase 2RecruitingZhejiang Cancer HospitalApr 20, 2026
    Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasCarmustine—Active, not recruitingBlokhin's Russian Cancer Research CenterMar 4, 2026
    Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentCarmustinePhase 2RecruitingRuijin HospitalSep 30, 2025
    Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized TrialCarmustinePhase 4RecruitingChinese PLA General HospitalAug 3, 2025
    A Study of Carmustine With and Without Ethanol in Subjects With LymphomaCarmustinePhase 2RecruitingVIVUS LLCApr 8, 2025
    CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantCarmustinePhase 2RecruitingWashington University School of MedicineNov 14, 2024
    Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveCarmustinePhase 2Not yet recruitingRuijin HospitalOct 22, 2024
    A Study of RSLV-132 in Females With Sjögren's DiseaseRSLV-132Phase 2Active, not recruitingResolve TherapeuticsJun 4, 2024

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2311222, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.